Disclosure: This study was sponsored by Pfizer, Inc. The sponsorship from Pfizer was not contingent upon the study results. Pfizer participated in the study design, results interpretation, and manuscript preparation as reflected in the authorship by Pfizer employees, DS and JM. AJ was a full-time Pfizer employee at the time the study was conducted and the manuscript was drafted. WC, CK, HB, RA, ZZ, and MSD are employees of Analysis Group, Inc., which were paid consultants to Pfizer in connection with the development of this manuscript. EM has no disclosures to declare.
Systematic Literature Review and Meta-Analysis of the Efficacy and Safety of Prescription Opioids, Including Abuse-Deterrent Formulations, in Non-Cancer Pain Management
Article first published online: 23 SEP 2013
Wiley Periodicals, Inc
Volume 15, Issue 1, pages 79–92, January 2014
How to Cite
Michna, E., Cheng, W. Y., Korves, C., Birnbaum, H., Andrews, R., Zhou, Z., Joshi, A. V., Schaaf, D., Mardekian, J. and Sheng, M. (2014), Systematic Literature Review and Meta-Analysis of the Efficacy and Safety of Prescription Opioids, Including Abuse-Deterrent Formulations, in Non-Cancer Pain Management. Pain Medicine, 15: 79–92. doi: 10.1111/pme.12233
- Issue published online: 16 JAN 2014
- Article first published online: 23 SEP 2013
- Pfizer, Inc
- 1American Pain Society. Pain assessment and treatment in the managed care environment. A position statement from the American Pain Society. Case Manager 2000;11(5):50–53.
- 2Committee on Advancing Pain Research C, Education, Medicine Io. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
- 4Administration SAaMHS. Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies NSH-, DHHS Publication No. SMA 09–4434, editor. Rockville, MD 2009.
- 7De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008;24(6):521–527., , , et al.
- 9Special topics in statistics. In: Higgins JPT , Deeks JJ , Altman DG , eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available at: www.cochrane-handbook.org (accessed September 2013)., .
- 11Indirect treatment comparison [computer program], 1.0 edition. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009., , , , .
- 14StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
- 16Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23(4):278–291., , , et al.
- 19A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 2006;28(3):352–364., , , .
- 21Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005;6(5):357–366., , .
- 23Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 2008;4(2):87–97., , , , .
- 29Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010;122(4):112–128., , , .
- 30Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 2011;7(3):193–202., , .
- 35Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007;29(5):874–888., , , .
- 42Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain. J Opioid Manag 2011;7(3):217–228., , , .
- 49Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30(8):489–505., , , et al.
- 52Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: A single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 2010;32(6):1149–1164., , , .
- 54Feasibility study of rapid opioid rotation and titration. Pain Physician 2011;14(1):71–82., , , , .
- 57A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial. J Opioid Manag 2007;3(1):35–43., , , et al.
- 58A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: The extension phase of the ACTION trial. J Opioid Manag 2006;2(6):325–328, 31–3., , , et al.
- 59The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2006;2(3):155–166., , , et al.
- 60Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): Findings from a pilot study. J Opioid Manag 2007;3(3):145–154., , , et al.
- 61Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009;29(12):777–790., , , et al.
- 63Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010;40(5):734–746., , , et al.
- 64Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D 2011;11(3):259–275., , , , .
- 68Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study. Am J Ther 2005;12(2):106–112., .
- 77Oral once-a-day AVINZA (morphine sulfate extended release capsules) vs. twice daily OxyContin (oxycodone hydrochloride controlled-release) for the treatment of chronic moderate to severe low back pain; final (part I and part II) study results 84 3102. J Pain 2006;4(7):S57., , , et al.
- 78Randomized, double-blind, placebo-controlled 12-week study assessing the efficacy of oxymorphone extended release in opioid-naïve patients with chronic low back pain 83 3101. J Pain 2006;5(7):S55., , , et al.
- 79Oral once-a-day AVINZA (morphine sulfate extended release capsules) vs. twice daily OxyContin (oxycodone hydrochloride controlled-release): A randomized, multi-centre study for the treatment of chronic moderate to severe low back pain 82 3100. J Pain 2006;3(7):S54., , , et al.